BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hezel AF, Zhu AX. Systemic Therapy for Biliary Tract Cancers. The Oncol 2008;13:415-23. [DOI: 10.1634/theoncologist.2007-0252] [Cited by in Crossref: 150] [Cited by in F6Publishing: 137] [Article Influence: 11.5] [Reference Citation Analysis]
Number Citing Articles
1 Srijiwangsa P, Ponnikorn S, Na-Bangchang K. Effect of β-Eudesmol on NQO1 suppression-enhanced sensitivity of cholangiocarcinoma cells to chemotherapeutic agents. BMC Pharmacol Toxicol 2018;19:32. [PMID: 29914576 DOI: 10.1186/s40360-018-0223-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
2 Zhang H, Yang T, Wu M, Shen F. Intrahepatic cholangiocarcinoma: Epidemiology, risk factors, diagnosis and surgical management. Cancer Letters 2016;379:198-205. [DOI: 10.1016/j.canlet.2015.09.008] [Cited by in Crossref: 91] [Cited by in F6Publishing: 77] [Article Influence: 18.2] [Reference Citation Analysis]
3 Zhu AX, Hong TS, Hezel AF, Kooby DA. Current management of gallbladder carcinoma. Oncologist. 2010;15:168-181. [PMID: 20147507 DOI: 10.1634/theoncologist.2009-0302] [Cited by in Crossref: 184] [Cited by in F6Publishing: 146] [Article Influence: 16.7] [Reference Citation Analysis]
4 Prompipak J, Senawong T, Sripa B, Ketterman AJ, Utaiwat S, Woranam K, Jeeunngoi J, Senawong G. Anticancer effects of the combined Thai noni juice ethanolic extracts and 5-fluorouracil against cholangiocarcinoma cells in vitro and in vivo. Sci Rep 2021;11:14866. [PMID: 34290264 DOI: 10.1038/s41598-021-94049-z] [Reference Citation Analysis]
5 Pollom EL, Alagappan M, Park LS, Whittemore AS, Koong AC, Chang DT. Does radiotherapy still have a role in unresected biliary tract cancer? Cancer Med. 2017;6:129-141. [PMID: 27891822 DOI: 10.1002/cam4.975] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
6 Lu Y, Yan B, Guo H, Qiu L, Sun X, Wang X, Shi Q, Bao Y. Effect of midkine on gemcitabine resistance in biliary tract cancer. Int J Mol Med 2018;41:2003-11. [PMID: 29344648 DOI: 10.3892/ijmm.2018.3399] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
7 Ramírez-Merino N, Aix SP, Cortés-Funes H. Chemotherapy for cholangiocarcinoma: An update. World J Gastrointest Oncol. 2013;5:171-176. [PMID: 23919111 DOI: 10.4251/wjgo.v5.i7.171] [Cited by in CrossRef: 67] [Cited by in F6Publishing: 66] [Article Influence: 8.4] [Reference Citation Analysis]
8 Hashimoto K, Miller CM. Liver transplantation for intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Sci. 2015;22:138-143. [PMID: 25214036 DOI: 10.1002/jhbp.159] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
9 Reames BN, Bagante F, Ejaz A, Spolverato G, Ruzzenente A, Weiss M, Alexandrescu S, Marques HP, Aldrighetti L, Maithel SK, Pulitano C, Bauer TW, Shen F, Poultsides GA, Soubrane O, Martel G, Koerkamp BG, Guglielmi A, Itaru E, Pawlik TM. Impact of adjuvant chemotherapy on survival in patients with intrahepatic cholangiocarcinoma: a multi-institutional analysis. HPB (Oxford) 2017;19:901-9. [PMID: 28728891 DOI: 10.1016/j.hpb.2017.06.008] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 10.3] [Reference Citation Analysis]
10 Nonaka Y, Nanashima A, Nonaka T, Uehara M, Isomoto H, Abo T, Nagayasu T. Synergic effect of photodynamic therapy using talaporfin sodium with conventional anticancer chemotherapy for the treatment of bile duct carcinoma. J Surg Res 2013;181:234-41. [PMID: 22835954 DOI: 10.1016/j.jss.2012.06.047] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
11 Lim JH, Ryu JK, Choi YJ, Kwon J, Kim JY, Lee YB, Kim JH, Yoon WJ, Kim YT, Yoon YB. A Case of Common Bile Duct Cancer That Completely Responded to Combination Chemotherapy of Gemcitabine and TS-1. Gut Liver. 2013;7:371-376. [PMID: 23710321 DOI: 10.5009/gnl.2013.7.3.371] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
12 Hung SP, Huang BS, Hsieh CE, Lee CH, Tsang NM, Chang JT, Chen JS, Chou WC, Tseng JH, Hong JH. Clinical Outcomes of Patients With Unresectable Cholangiocarcinoma Treated With Proton Beam Therapy. Am J Clin Oncol 2020;43:180-6. [PMID: 31764017 DOI: 10.1097/COC.0000000000000646] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
13 Braconi C, Patel T. Cholangiocarcinoma: new insights into disease pathogenesis and biology. Infect Dis Clin North Am. 2010;24:871-84, vii. [PMID: 20937455 DOI: 10.1016/j.idc.2010.07.006] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 4.3] [Reference Citation Analysis]
14 Abe K, Wakatsuki T, Katsushima F, Monoe K, Kanno Y, Takahashi A, Yokokawa J, Ohira H. A case of advanced intrahepatic cholangiocarcinoma successfully treated with chemosensitivity test-guided systemic chemotherapy. World J Gastroenterol 2009;15:5228-31. [PMID: 19891026 DOI: 10.3748/wjg.15.5228] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
15 Nguyen NA, Timotin E, Hunter R, Sur RK. High-dose rate intraluminal brachytherapy: An effective palliation for cholangiocarcinoma causing bile duct obstruction. Surgical Oncology 2018;27:625-9. [DOI: 10.1016/j.suronc.2018.07.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
16 Park JO, Oh DY, Hsu C, Chen JS, Chen LT, Orlando M, Kim JS, Lim HY. Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review. Cancer Res Treat 2015;47:343-61. [PMID: 25989801 DOI: 10.4143/crt.2014.308] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 5.3] [Reference Citation Analysis]
17 Weber SM, Ribero D, O'Reilly EM, Kokudo N, Miyazaki M, Pawlik TM. Intrahepatic cholangiocarcinoma: expert consensus statement. HPB (Oxford). 2015;17:669-680. [PMID: 26172134 DOI: 10.1111/hpb.12441] [Cited by in Crossref: 177] [Cited by in F6Publishing: 149] [Article Influence: 35.4] [Reference Citation Analysis]
18 Brandi G, Venturi M, Pantaleo MA, Ercolani G;  GICO. Cholangiocarcinoma: Current opinion on clinical practice diagnostic and therapeutic algorithms: A review of the literature and a long-standing experience of a referral center. Dig Liver Dis. 2016;48:231-241. [PMID: 26769568 DOI: 10.1016/j.dld.2015.11.017] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 8.0] [Reference Citation Analysis]
19 Haga H, Patel T. Molecular diagnosis of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Sci 2015;22:114-23. [PMID: 25267595 DOI: 10.1002/jhbp.156] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
20 Woo HY, Yoo SY, Heo J. New chemical treatment options in second-line hepatocellular carcinoma: what to do when sorafenib fails? Expert Opin Pharmacother. 2017;18:35-44. [PMID: 27849399 DOI: 10.1080/14656566.2016.1261825] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
21 Subbiah IM, Subbiah V, Tsimberidou AM, Naing A, Kaseb AO, Javle M, Fu S, Hong DS, Piha-Paul S, Wheler JJ, Hess KR, Janku F, Falchook GS, Wolff RA, Kurzrock R. Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. Oncotarget 2013;4:156-65. [PMID: 23391555 DOI: 10.18632/oncotarget.832] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
22 Kobayashi M, Sakabe T, Abe H, Tanii M, Takahashi H, Chiba A, Yanagida E, Shibamoto Y, Ogasawara M, Tsujitani S, Koido S, Nagai K, Shimodaira S, Okamoto M, Yonemitsu Y, Suzuki N, Nagaya M; DC-vaccine study group at the Japan Society of Innovative Cell Therapy (J-SICT). Dendritic cell-based immunotherapy targeting synthesized peptides for advanced biliary tract cancer. J Gastrointest Surg. 2013;17:1609-1617. [PMID: 23877328 DOI: 10.1007/s11605-013-2286-2] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 5.9] [Reference Citation Analysis]
23 Huang L, Frampton G, Liang LJ, Demorrow S. Aberrant DNA methylation profile in cholangiocarcinoma. World J Gastrointest Pathophysiol. 2010;1:23-29. [PMID: 21607139 DOI: 10.4291/wjgp.v1.i2.23] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
24 Marks EI, Yee NS. Molecular genetics and targeted therapeutics in biliary tract carcinoma. World J Gastroenterol. 2016;22:1335-1347. [PMID: 26819503 DOI: 10.3748/wjg.v22.i4.1335] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 32] [Article Influence: 8.5] [Reference Citation Analysis]
25 Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, O’Neil BH, Balsom S, Balint C, Liersemann R. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol. 2011;29:2357-2363. [PMID: 21519026 DOI: 10.1200/jco.2010.33.9473] [Cited by in Crossref: 202] [Cited by in F6Publishing: 102] [Article Influence: 20.2] [Reference Citation Analysis]
26 Javle M, Bekaii-Saab T, Jain A, Wang Y, Kelley RK, Wang K, Kang HC, Catenacci D, Ali S, Krishnan S, Ahn D, Bocobo AG, Zuo M, Kaseb A, Miller V, Stephens PJ, Meric-Bernstam F, Shroff R, Ross J. Biliary cancer: Utility of next-generation sequencing for clinical management. Cancer. 2016;122:3838-3847. [PMID: 27622582 DOI: 10.1002/cncr.30254] [Cited by in Crossref: 127] [Cited by in F6Publishing: 111] [Article Influence: 25.4] [Reference Citation Analysis]
27 Saboo SS, Krajewski KM, Jagannathan JP, O'Regan KN, Odze R, Ramaiya N, Wolpin BM. Rapid progression of combined hepatocellular carcinoma and cholangiocarcinoma. Cancer Imaging 2011;11:37-41. [PMID: 21507775 DOI: 10.1102/1470-7330.2011.0009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
28 Bréchon M, Dior M, Dréanic J, Brieau B, Guillaumot M, Brezault C, Mir O, Goldwasser F, Coriat R. Addition of an antiangiogenic therapy, bevacizumab, to gemcitabine plus oxaliplatin improves survival in advanced biliary tract cancers. Invest New Drugs 2018;36:156-62. [DOI: 10.1007/s10637-017-0492-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
29 Ghosn M, Kourie HR, El Rassy E, Chebib R, El Karak F, Hanna C, Nasr D. Optimum chemotherapy for the management of advanced biliary tract cancer. World J Gastroenterol 2015;21:4121-5. [PMID: 25892861 DOI: 10.3748/wjg.v21.i14.4121] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
30 Hirata K, Kuwatani M, Suda G, Ishikawa M, Sugiura R, Kato S, Kawakubo K, Sakamoto N. A Novel Approach for the Genetic Analysis of Biliary Tract Cancer Specimens Obtained Through Endoscopic Ultrasound-Guided Fine Needle Aspiration Using Targeted Amplicon Sequencing. Clin Transl Gastroenterol 2019;10:e00022. [PMID: 30908307 DOI: 10.14309/ctg.0000000000000022] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
31 Lee DG, Lee SH, Kim JS, Park J, Cho YL, Kim KS, Jo DY, Song IC, Kim N, Yun HJ, Park YJ, Lee SJ, Lee HG, Bae KH, Lee SC, Shim S, Kim YM, Kwon YG, Kim JM, Lee HJ, Min JK. Loss of NDRG2 promotes epithelial-mesenchymal transition of gallbladder carcinoma cells through MMP-19-mediated Slug expression. J Hepatol 2015;63:1429-39. [PMID: 26292259 DOI: 10.1016/j.jhep.2015.08.007] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 4.7] [Reference Citation Analysis]
32 Suzuki E, Ikeda M, Okusaka T, Nakamori S, Ohkawa S, Nagakawa T, Boku N, Yanagimoto H, Sato T, Furuse J. A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer. Cancer Chemother Pharmacol 2013;71:1141-6. [PMID: 23525694 DOI: 10.1007/s00280-013-2106-0] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
33 Jo J, Kwon HW, Park S, Oh D, Cheon GJ, Bang Y. Prospective Evaluation of the Clinical Implications of the Tumor Metabolism and Chemotherapy-Related Changes in Advanced Biliary Tract Cancer. J Nucl Med 2017;58:1255-61. [DOI: 10.2967/jnumed.116.186239] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
34 Lee SE, Kim KS, Kim WB, Kim IG, Nah YW, Ryu DH, Park JS, Yoon MH, Cho JY, Hong TH, Hwang DW, Choi DW; Korean Association of Hepato-Biliary and Pancreas Surgery. Practical guidelines for the surgical treatment of gallbladder cancer. J Korean Med Sci 2014;29:1333-40. [PMID: 25368485 DOI: 10.3346/jkms.2014.29.10.1333] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 4.6] [Reference Citation Analysis]
35 Wirasorn K, Ngamprasertchai T, Khuntikeo N, Pakkhem A, Ungarereevittaya P, Chindaprasirt J, Sookprasert A. Adjuvant chemotherapy in resectable cholangiocarcinoma patients. J Gastroenterol Hepatol. 2013;28:1885-1891. [PMID: 23829232 DOI: 10.1111/jgh.12321] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
36 Dickson PV, Behrman SW. Distal Cholangiocarcinoma. Surgical Clinics of North America 2014;94:325-42. [DOI: 10.1016/j.suc.2013.12.004] [Cited by in Crossref: 28] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
37 Seehofer D, Kamphues C, Neuhaus P. Management of bile duct tumors. Expert Opin Pharmacother. 2008;9:2843-2856. [PMID: 18937616 DOI: 10.1517/14656566.9.16.2843] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
38 Au TH, Wang K, Stenehjem D, Garrido-Laguna I. Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies. J Gastrointest Oncol 2017;8:387-404. [PMID: 28736627 DOI: 10.21037/jgo.2017.01.04] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
39 Sergeant G, Lerut E, Ectors N, Hendrickx T, Aerts R, Topal B. The prognostic relevance of tumor hypoxia markers in resected carcinoma of the gallbladder. Eur J Surg Oncol 2011;37:80-6. [PMID: 21109386 DOI: 10.1016/j.ejso.2010.10.007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
40 Mao ZY, Guo XC, Su D, Wang LJ, Zhang TT, Bai L. Prognostic Factors of Cholangiocarcinoma After Surgical Resection: A Retrospective Study of 293 Patients. Med Sci Monit 2015;21:2375-81. [PMID: 26269932 DOI: 10.12659/MSM.893586] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
41 Hwang JP, Lim I, Na II, Cho EH, Kim BI, Choi CW, Lim SM. Prognostic Value of SUVmax Measured by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography with Computed Tomography in Patients with Gallbladder Cancer. Nucl Med Mol Imaging 2014;48:114-20. [PMID: 24900151 DOI: 10.1007/s13139-013-0255-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
42 Sebastian NT, Tan Y, Miller ED, Williams TM, Noonan AM, Hays JL, Abdel-Misih S, Diaz DA. Association of Liver-Directed Local Therapy With Overall Survival in Adults With Metastatic Intrahepatic Cholangiocarcinoma. JAMA Netw Open. 2019;2:e1911154. [PMID: 31517963 DOI: 10.1001/jamanetworkopen.2019.11154] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
43 Pan TT, Wang W, Jia WD, Xu GL. A single-center experience of sorafenib monotherapy in patients with advanced intrahepatic cholangiocarcinoma. Oncol Lett 2017;13:2957-64. [PMID: 28529557 DOI: 10.3892/ol.2017.5847] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
44 Hahnvajanawong C, Chaiyagool J, Seubwai W, Bhudhisawasdi V, Namwat N, Khuntikeo N, Sripa B, Pugkhem A, Tassaneeyakul W. Orotate phosphoribosyl transferase mRNA expression and the response of cholangiocarcinoma to 5-fluorouracil. World J Gastroenterol 2012;18:3955-61. [PMID: 22912546 DOI: 10.3748/wjg.v18.i30.3955] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
45 Ahn DH, Javle M, Ahn CW, Jain A, Mikhail S, Noonan AM, Ciombor K, Wu C, Shroff RT, Chen JL, Bekaii-Saab T. Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance. Cancer 2016;122:3657-66. [PMID: 27495988 DOI: 10.1002/cncr.30247] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 5.4] [Reference Citation Analysis]
46 Tonini G, Virzì V, Fratto ME, Vincenzi B, Santini D. Targeted therapy in biliary tract cancer: 2009 update. Future Oncol 2009;5:1675-84. [PMID: 20001803 DOI: 10.2217/fon.09.130] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
47 Shen ZT, Zhou H, Li AM, Li B, Shen JS, Zhu XX. Clinical outcomes and prognostic factors of stereotactic body radiation therapy for intrahepatic cholangiocarcinoma. Oncotarget. 2017;8:93541-93550. [PMID: 29212171 DOI: 10.18632/oncotarget.19972] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
48 Lee SY, Kim HS, Choi YJ, Park KH, Shin SW, Kim YH, Tae Kim S. A Prognostic Index to Identify Patients With Intrahepatic Cholangiocarcinoma Who Could Benefit From Gemcitabine Plus Cisplatin. Am J Ther 2016;23:e1449-55. [PMID: 25285672 DOI: 10.1097/MJT.0000000000000112] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
49 Sasaki T, Isayama H, Nakai Y, Togawa O, Kogure H, Ito Y, Yamamoto K, Mizuno S, Yagioka H, Yashima Y. Prognostic factors in patients with advanced biliary tract cancer receiving chemotherapy. Cancer Chemother Pharmacol. 2011;67:847-853. [PMID: 20563811 DOI: 10.1007/s00280-010-1360-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
50 Jensen LH, Jakobsen A. Combining biological agents and chemotherapy in the treatment of cholangiocarcinoma. Expert Review of Anticancer Therapy 2014;11:589-600. [DOI: 10.1586/era.11.17] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
51 Arai Y, Totoki Y, Hosoda F, Shirota T, Hama N, Nakamura H, Ojima H, Furuta K, Shimada K, Okusaka T. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology. 2014;59:1427-1434. [PMID: 24122810 DOI: 10.1002/hep.26890] [Cited by in Crossref: 237] [Cited by in F6Publishing: 214] [Article Influence: 33.9] [Reference Citation Analysis]
52 Kelley RK, Hirose R, Venook AP. Can we cure cholangiocarcinoma with neoadjuvant chemoradiation and liver transplantation? Time for a multicenter trial. Liver Transpl. 2012;18:509-513. [PMID: 22389236 DOI: 10.1002/lt.23423] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
53 Sasaki T, Isayama H, Nakai Y, Ito Y, Kogure H, Togawa O, Toda N, Yasuda I, Hasebe O, Maetani I. Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol. 2010;65:1101-1107. [PMID: 19707761 DOI: 10.1007/s00280-009-1115-5] [Cited by in Crossref: 73] [Cited by in F6Publishing: 57] [Article Influence: 6.1] [Reference Citation Analysis]
54 Rana A, Hong JC. Orthotopic liver transplantation in combination with neoadjuvant therapy: a new paradigm in the treatment of unresectable intrahepatic cholangiocarcinoma. Current Opinion in Gastroenterology 2012;28:258-65. [DOI: 10.1097/mog.0b013e32835168db] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
55 Razumilava N, Gores GJ. Combination of gemcitabine and cisplatin for biliary tract cancer: a platform to build on. J Hepatol 2011;54:577-8. [PMID: 21112109 DOI: 10.1016/j.jhep.2010.10.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
56 Kim HS, Kim HY, Zang DY, Oh HS, Jeon JY, Cho JW, Park CK, Kim JH, Kim MJ, Ha HI. Phase II study of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer. Cancer Chemother Pharmacol. 2015;75:711-718. [PMID: 25630414 DOI: 10.1007/s00280-015-2687-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
57 Moolmuang B, Ruchirawat M. The antiproliferative effects of ataxia-telangiectasia mutated and ATM- and Rad3-related inhibitions and their enhancements with the cytotoxicity of DNA damaging agents in cholangiocarcinoma cells. J Pharm Pharmacol 2021;73:40-51. [PMID: 33791808 DOI: 10.1093/jpp/rgaa050] [Reference Citation Analysis]
58 Buzzoni R, Pusceddu S, Bajetta E, De Braud F, Platania M, Iannacone C, Cantore M, Mambrini A, Bertolini A, Alabiso O. Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study. Ann Oncol. 2014;25:1597-1603. [PMID: 24827133 DOI: 10.1093/annonc/mdu175] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 5.3] [Reference Citation Analysis]
59 Turaga KK, Tsai S, Wiebe LA, Evans DB, Gamblin TC. Novel multimodality treatment sequencing for extrahepatic (mid and distal) cholangiocarcinoma. Ann Surg Oncol 2013;20:1230-9. [PMID: 23064778 DOI: 10.1245/s10434-012-2648-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
60 Sasaki T, Isayama H, Nakai Y, Koike K. Current status of chemotherapy for the treatment of advanced biliary tract cancer. Korean J Intern Med. 2013;28:515-524. [PMID: 24009445 DOI: 10.3904/kjim.2013.28.5.515] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
61 Bengala C, Bertolini F, Malavasi N, Boni C, Aitini E, Dealis C, Zironi S, Depenni R, Fontana A, Del Giovane C. Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. Br J Cancer. 2010;102:68-72. [PMID: 19935794 DOI: 10.1038/sj.bjc.6605458] [Cited by in Crossref: 147] [Cited by in F6Publishing: 138] [Article Influence: 12.3] [Reference Citation Analysis]
62 Bupathi M, Ahn DH, Bekaii-Saab T. Therapeutic options for intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr 2017;6:91-100. [PMID: 28503556 DOI: 10.21037/hbsn.2016.12.12] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
63 Samatiwat P, Prawan A, Senggunprai L, Kukongviriyapan V. Repression of Nrf2 enhances antitumor effect of 5-fluorouracil and gemcitabine on cholangiocarcinoma cells. Naunyn-Schmiedeberg's Arch Pharmacol 2015;388:601-12. [DOI: 10.1007/s00210-015-1101-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
64 Morizane C, Okusaka T, Mizusawa J, Takashima A, Ueno M, Ikeda M, Hamamoto Y, Ishii H, Boku N, Furuse J. Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805). Cancer Sci 2013;104:1211-6. [PMID: 23763511 DOI: 10.1111/cas.12218] [Cited by in Crossref: 72] [Cited by in F6Publishing: 53] [Article Influence: 9.0] [Reference Citation Analysis]
65 Kongpetch S, Kukongviriyapan V, Prawan A, Senggunprai L, Kukongviriyapan U, Buranrat B. Crucial role of heme oxygenase-1 on the sensitivity of cholangiocarcinoma cells to chemotherapeutic agents. PLoS One 2012;7:e34994. [PMID: 22514698 DOI: 10.1371/journal.pone.0034994] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 5.7] [Reference Citation Analysis]
66 Choi JH, Lee SH, You MS, Shin BS, Choi YH, Kang J, Jang S, Paik WH, Ryu JK, Kim YT. Step-wise endoscopic approach to palliative bilateral biliary drainage for unresectable advanced malignant hilar obstruction. Sci Rep 2019;9:13207. [PMID: 31519930 DOI: 10.1038/s41598-019-48384-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Benson AB, Abrams TA, Ben-Josef E, Bloomston PM, Botha JF, Clary BM, Covey A, Curley SA, D'Angelica MI, Davila R, Ensminger WD, Gibbs JF, Laheru D, Malafa MP, Marrero J, Meranze SG, Mulvihill SJ, Park JO, Posey JA, Sachdev J, Salem R, Sigurdson ER, Sofocleous C, Vauthey JN, Venook AP, Goff LW, Yen Y, Zhu AX. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw. 2009;7:350-391. [PMID: 19406039 DOI: 10.6004/jnccn.2009.0027] [Cited by in Crossref: 299] [Cited by in F6Publishing: 299] [Article Influence: 24.9] [Reference Citation Analysis]
68 Ikeda M, Ioka T, Fukutomi A, Morizane C, Kasuga A, Takahashi H, Todaka A, Okusaka T, Creasy CL, Gorman S, Felitsky DJ, Kobayashi M, Zhang F, Furuse J. Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine. Cancer Sci 2018;109:215-24. [PMID: 29121415 DOI: 10.1111/cas.13438] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
69 Mehra S, Panwar R, Thakur B, Yadav R, Kumar M, Singh R, Dash NR, Sahni P, Chauhan SS. Expression and Clinical Implications of Cysteine Cathepsins in Gallbladder Carcinoma. Front Oncol 2019;9:1239. [PMID: 31824841 DOI: 10.3389/fonc.2019.01239] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
70 Zhu AX, Hezel AF. Development of molecularly targeted therapies in biliary tract cancers: Reassessing the challenges and opportunities. Hepatology 2011;53:695-704. [DOI: 10.1002/hep.24145] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 5.2] [Reference Citation Analysis]
71 Li P, Zhang L, Yang M, Qi M, Jin X, Han B. Cul4B is a novel prognostic marker in cholangiocarcinoma. Oncol Lett 2017;14:1265-74. [PMID: 28808481 DOI: 10.3892/ol.2017.6297] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
72 Morera Ocón FJ, Ballestín Vicente J, Ripoll Orts F, Landete Molina F, García-Granero Ximénez M, Millán Tarín J, Tursi Rispoldi Ld, Bernal Sprekelsen JC. [Gallbladder cancer in a regional hospital]. Cir Esp 2009;86:219-23. [PMID: 19695566 DOI: 10.1016/j.ciresp.2009.02.021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
73 Mazzaferro V, El-Rayes BF, Droz Dit Busset M, Cotsoglou C, Harris WP, Damjanov N, Masi G, Rimassa L, Personeni N, Braiteh F, Zagonel V, Papadopoulos KP, Hall T, Wang Y, Schwartz B, Kazakin J, Bhoori S, de Braud F, Shaib WL. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. Br J Cancer. 2019;120:165-171. [PMID: 30420614 DOI: 10.1038/s41416-018-0334-0] [Cited by in Crossref: 110] [Cited by in F6Publishing: 92] [Article Influence: 36.7] [Reference Citation Analysis]
74 Wagner AD, Buechner-Steudel P, Moehler M, Schmalenberg H, Behrens R, Fahlke J, Wein A, Behl S, Kuss O, Kleber G, Fleig WE. Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials. Br J Cancer 2009;101:1846-52. [PMID: 19904267 DOI: 10.1038/sj.bjc.6605377] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
75 Beaulieu C, Lui A, Yusuf D, Abdelaziz Z, Randolph B, Batuyong E, Ghosh S, Bathe OF, Tam V, Spratlin JL. A Population-Based Retrospective Study of Biliary Tract Cancers in Alberta, Canada. Curr Oncol 2021;28:417-27. [PMID: 33450805 DOI: 10.3390/curroncol28010044] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
76 Miyamoto M, Ojima H, Iwasaki M, Shimizu H, Kokubu A, Hiraoka N, Kosuge T, Yoshikawa D, Kono T, Furukawa H. Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma. Br J Cancer. 2011;105:131-138. [PMID: 21673683 DOI: 10.1038/bjc.2011.199] [Cited by in Crossref: 73] [Cited by in F6Publishing: 74] [Article Influence: 7.3] [Reference Citation Analysis]
77 Patel T. Cholangiocarcinoma--controversies and challenges. Nat Rev Gastroenterol Hepatol. 2011;8:189-200. [PMID: 21460876 DOI: 10.1038/nrgastro.2011.20] [Cited by in Crossref: 204] [Cited by in F6Publishing: 176] [Article Influence: 20.4] [Reference Citation Analysis]
78 Chen YX, Zeng ZC, Tang ZY, Fan J, Zhou J, Jiang W, Zeng MS, Tan YS. Determining the role of external beam radiotherapy in unresectable intrahepatic cholangiocarcinoma: a retrospective analysis of 84 patients. BMC Cancer 2010;10:492. [PMID: 20840777 DOI: 10.1186/1471-2407-10-492] [Cited by in Crossref: 56] [Cited by in F6Publishing: 44] [Article Influence: 5.1] [Reference Citation Analysis]
79 Bernocchi O, Sirico M, Corona SP, Strina C, Milani M, Cappelletti MR, Ferrero G, Ziglioli N, Cervoni V, Macchiavelli A, Roviello G, Generali D. Tumor Type Agnostic Therapy Carrying BRAF Mutation: Case Reports and Review of Literature. Pharmaceuticals (Basel) 2021;14:159. [PMID: 33669326 DOI: 10.3390/ph14020159] [Reference Citation Analysis]
80 Kittiratphatthana N, Kukongviriyapan V, Prawan A, Senggunprai L. Luteolin induces cholangiocarcinoma cell apoptosis through the mitochondrial-dependent pathway mediated by reactive oxygen species. J Pharm Pharmacol 2016;68:1184-92. [PMID: 27334841 DOI: 10.1111/jphp.12586] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
81 Sun D, Ma J, Wang J, Han C, Qian Y, Chen G, Li X, Zhang J, Cui P, Du W, Wu Z, Chen S, Zheng X, Yue Z, Song J, Gao C, Zhao X, Cai S, Hu Y. Anti-PD-1 therapy combined with chemotherapy in patients with advanced biliary tract cancer. Cancer Immunol Immunother 2019;68:1527-35. [PMID: 31535160 DOI: 10.1007/s00262-019-02386-w] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
82 Kyrochristos ID, Glantzounis GK, Ziogas DE, Gizas I, Schizas D, Lykoudis EG, Felekouras E, Machairas A, Katsios C, Liakakos T, Cho WC, Roukos DH. From Clinical Standards to Translating Next-Generation Sequencing Research into Patient Care Improvement for Hepatobiliary and Pancreatic Cancers. Int J Mol Sci 2017;18:E180. [PMID: 28106782 DOI: 10.3390/ijms18010180] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
83 Shen WF, Zhong W, Liu Q, Sui CJ, Huang YQ, Yang JM. Adjuvant transcatheter arterial chemoembolization for intrahepatic cholangiocarcinoma after curative surgery: retrospective control study. World J Surg. 2011;35:2083-2091. [PMID: 21698503 DOI: 10.1007/s00268-011-1171-y] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 4.1] [Reference Citation Analysis]
84 Tusskorn O, Prawan A, Senggunprai L, Kukongviriyapan U, Kukongviriyapan V. Phenethyl isothiocyanate induces apoptosis of cholangiocarcinoma cells through interruption of glutathione and mitochondrial pathway. Naunyn Schmiedebergs Arch Pharmacol 2013;386:1009-16. [PMID: 23949086 DOI: 10.1007/s00210-013-0906-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
85 Feng F, Cheng Q, Li B, Liu C, Wang H, Li B, Xu X, Yu Y, Chen Z, Wu X, Dong H, Chu K, Xie Z, Gao Q, Xiong L, Li F, Yi B, Zhang D, Jiang X. Establishment and characterization of 38 novel patient-derived primary cancer cell lines using multi-region sampling revealing intra-tumor heterogeneity of gallbladder carcinoma. Hum Cell 2021;34:918-31. [PMID: 33813726 DOI: 10.1007/s13577-021-00492-5] [Reference Citation Analysis]
86 Hwang JS, So H, Song TJ. Percutaneous endobiliary radiofrequency ablation for tumor ingrowth causing metal stent obstruction. Dig Endosc 2020;32:e132-3. [PMID: 32783301 DOI: 10.1111/den.13760] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
87 Lafaro KJ, Cosgrove D, Geschwind JF, Kamel I, Herman JM, Pawlik TM. Multidisciplinary Care of Patients with Intrahepatic Cholangiocarcinoma: Updates in Management. Gastroenterol Res Pract 2015;2015:860861. [PMID: 26089873 DOI: 10.1155/2015/860861] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 4.5] [Reference Citation Analysis]
88 Hoang BX, Tran HQ, Vu UV, Pham QT, Shaw DG. Palliative Treatment for Advanced Biliary Adenocarcinomas With Combination Dimethyl Sulfoxide–Sodium Bicarbonate Infusion and S -Adenosyl-L-Methionine. Journal of Pain & Palliative Care Pharmacotherapy 2014;28:206-11. [DOI: 10.3109/15360288.2014.938882] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
89 Buettner S, Ethun CG, Poultsides G, Tran T, Idrees K, Isom CA, Weiss M, Fields RC, Krasnick B, Weber SM, Salem A, Martin RCG, Scoggins CR, Shen P, Mogal HD, Schmidt C, Beal E, Hatzaras I, Shenoy R, Koerkamp BG, Maithel SK, Pawlik TM. Surgical Site Infection Is Associated with Tumor Recurrence in Patients with Extrahepatic Biliary Malignancies. J Gastrointest Surg 2017;21:1813-20. [PMID: 28913712 DOI: 10.1007/s11605-017-3571-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
90 Jensen LH, Andersen RF, Byriel L, Fernebro E, Jakobsen A, Lindebjerg J, Nottelmann L, Ploen J, Hansen TF. Phase II study of gemcitabine, oxaliplatin and capecitabine in patients with KRAS exon 2 mutated biliary tract cancers. Acta Oncol 2020;59:298-301. [PMID: 31838939 DOI: 10.1080/0284186X.2019.1701201] [Reference Citation Analysis]
91 Groot Koerkamp B, Fong Y. Outcomes in biliary malignancy. J Surg Oncol. 2014;110:585-591. [PMID: 25250887 DOI: 10.1002/jso.23762] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 6.4] [Reference Citation Analysis]
92 Dutta U. Gallbladder cancer: can newer insights improve the outcome? J Gastroenterol Hepatol. 2012;27:642-653. [PMID: 22168580 DOI: 10.1111/j.1440-1746.2011.07048.x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 56] [Article Influence: 7.1] [Reference Citation Analysis]
93 Takahashi H, Ojima H, Shimizu H, Furuse J, Furukawa H, Shibata T. Axitinib (AG-013736), an oral specific VEGFR TKI, shows potential therapeutic utility against cholangiocarcinoma. Jpn J Clin Oncol. 2014;44:570-578. [PMID: 24755544 DOI: 10.1093/jjco/hyu045] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
94 Oyasiji T, Zhang J, Kuvshinoff B, Iyer R, Hochwald SN. Molecular Targets in Biliary Carcinogenesis and Implications for Therapy. Oncologist 2015;20:742-51. [PMID: 26025932 DOI: 10.1634/theoncologist.2014-0442] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
95 Mohri D, Ijichi H, Miyabayashi K, Takahashi R, Kudo Y, Sasaki T, Asaoka Y, Tanaka Y, Ikenoue T, Tateishi K, Tada M, Isayama H, Koike K. A potent therapeutics for gallbladder cancer by combinatorial inhibition of the MAPK and mTOR signaling networks. J Gastroenterol 2016;51:711-21. [PMID: 26614007 DOI: 10.1007/s00535-015-1145-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
96 Lee J, Hong TH, Lee IS, You YK, Lee MA. Comparison of the Efficacy between Gemcitabine-Cisplatin and Capecitabine-Cisplatin Combination Chemotherapy for Advanced Biliary Tract Cancer. Cancer Res Treat 2015;47:259-65. [PMID: 25648099 DOI: 10.4143/crt.2013.230] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
97 Shaker TM, Chung C, Varma MK, Doherty MG, Wolf AM, Chung MH, Assifi MM. Is there a role for Ytrrium-90 in the treatment of unresectable and metastatic intrahepatic cholangiocarcinoma? The American Journal of Surgery 2018;215:467-70. [DOI: 10.1016/j.amjsurg.2017.11.022] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
98 Li F, Peiris MN, Donoghue DJ. Functions of FGFR2 corrupted by translocations in intrahepatic cholangiocarcinoma. Cytokine Growth Factor Rev 2020;52:56-67. [PMID: 31899106 DOI: 10.1016/j.cytogfr.2019.12.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
99 Schmidt A, Bloechinger M, Weber A, Siveke J, von Delius S, Prinz C, Schmitt W, Schmid RM, Neu B. Short-term effects and adverse events of endoscopically applied radiofrequency ablation appear to be comparable with photodynamic therapy in hilar cholangiocarcinoma. United European Gastroenterol J 2016;4:570-9. [PMID: 27536367 DOI: 10.1177/2050640615621235] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
100 Zhuang X, Xiao YP, Tan LH, Wang LT, Cao Q, Qu GF, Xiao S, Duan HX. Efficacy and safety of chemotherapy with or without targeted therapy in biliary tract cancer: A meta-analysis of 7 randomized controlled trials. J Huazhong Univ Sci Technolog Med Sci 2017;37:172-8. [PMID: 28397047 DOI: 10.1007/s11596-017-1711-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
101 Zhu AX, Meyerhardt JA, Blaszkowsky LS, Kambadakone AR, Muzikansky A, Zheng H, Clark JW, Abrams TA, Chan JA, Enzinger PC, Bhargava P, Kwak EL, Allen JN, Jain SR, Stuart K, Horgan K, Sheehan S, Fuchs CS, Ryan DP, Sahani DV. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol. 2010;11:48-54. [PMID: 19932054 DOI: 10.1016/s1470-2045(09)70333-x] [Cited by in Crossref: 194] [Cited by in F6Publishing: 86] [Article Influence: 16.2] [Reference Citation Analysis]
102 El-Khoueiry AB, Rankin CJ, Ben-Josef E, Lenz HJ, Gold PJ, Hamilton RD, Govindarajan R, Eng C, Blanke CD. SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma. Invest New Drugs. 2012;30:1646-1651. [PMID: 21748296 DOI: 10.1007/s10637-011-9719-0] [Cited by in Crossref: 101] [Cited by in F6Publishing: 92] [Article Influence: 10.1] [Reference Citation Analysis]
103 Santini D, Virzi V, Vasile E, Vincenzi B, Catalano V, Graziano F, Masi G, Bronte G, Russo A, Falcone A, Tonini G. A Phase II Trial of Fixed-Dose Rate Gemcitabine plus Capecitabine in Metastatic/Advanced Biliary Tract Cancer Patients. Oncology 2012;82:75-82. [DOI: 10.1159/000329079] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
104 Yi SW, Kang DR, Kim KS, Park MS, Seong J, Park JY, Bang SM, Song SY, Chung JB, Park SW. Efficacy of concurrent chemoradiotherapy with 5-fluorouracil or gemcitabine in locally advanced biliary tract cancer. Cancer Chemother Pharmacol 2014;73:191-8. [PMID: 24322374 DOI: 10.1007/s00280-013-2340-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
105 Alanazi SA, Alanazi F, Haq N, Shakeel F, Badran MM, Harisa GI. Lipoproteins-Nanocarriers as a Promising Approach for Targeting Liver Cancer: Present Status and Application Prospects. Curr Drug Deliv 2020;17:826-44. [PMID: 32026776 DOI: 10.2174/1567201817666200206104338] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
106 Hari DM, Howard JH, Leung AM, Chui CG, Sim MS, Bilchik AJ. A 21-year analysis of stage I gallbladder carcinoma: is cholecystectomy alone adequate? HPB (Oxford). 2013;15:40-48. [PMID: 23216778 DOI: 10.1111/j.1477-2574.2012.00559.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 33] [Article Influence: 5.7] [Reference Citation Analysis]
107 van Gulik TM, Kloek JJ, Ruys AT, Busch OR, van Tienhoven GJ, Lameris JS, Rauws EA, Gouma DJ. Multidisciplinary management of hilar cholangiocarcinoma (Klatskin tumor): extended resection is associated with improved survival. Eur J Surg Oncol. 2011;37:65-71. [PMID: 21115233 DOI: 10.1016/j.ejso.2010.11.008] [Cited by in Crossref: 61] [Cited by in F6Publishing: 60] [Article Influence: 5.5] [Reference Citation Analysis]
108 Potkonjak M, Miura JT, Turaga KK, Johnston FM, Tsai S, Christians KK, Gamblin TC. Intrahepatic cholangiocarcinoma and gallbladder cancer: distinguishing molecular profiles to guide potential therapy. HPB (Oxford) 2015;17:1119-23. [PMID: 26374242 DOI: 10.1111/hpb.12504] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
109 Park I, Lee JL, Ryu MH, Kim TW, Sook Lee S, Hyun Park D, Soo Lee S, Wan Seo D, Koo Lee S, Kim MH. Prognostic factors and predictive model in patients with advanced biliary tract adenocarcinoma receiving first-line palliative chemotherapy. Cancer 2009;115:4148-55. [PMID: 19536892 DOI: 10.1002/cncr.24472] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 3.7] [Reference Citation Analysis]
110 Okumura T, Nakamura J, Kai K, Ide Y, Nakamura H, Koga H, Ide T, Miyoshi A, Kitahara K, Noshiro H. Curative resection of gallbladder cancer with liver invasion and hepatic metastasis after chemotherapy with gemcitabine plus S-1: report of a case. World J Surg Oncol 2014;12:326. [PMID: 25367161 DOI: 10.1186/1477-7819-12-326] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
111 Chin KM, Chua DWQ, Lee SY, Chan CY, Goh BKP. Outcome of minimally invasive liver resection for extrapancreatic biliary malignancies: A single-institutional experience. J Minim Access Surg 2021;17:69-75. [PMID: 31997786 DOI: 10.4103/jmas.JMAS_247_19] [Reference Citation Analysis]
112 Hezel AF, Deshpande V, Zhu AX. Genetics of biliary tract cancers and emerging targeted therapies. J Clin Oncol. 2010;28:3531-3540. [PMID: 20547994 DOI: 10.1200/jco.2009.27.4787] [Cited by in Crossref: 139] [Cited by in F6Publishing: 83] [Article Influence: 12.6] [Reference Citation Analysis]
113 Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, O'Neil BH, Balsom S, Balint C, Liersemann R, Vasko VV, Bloomston M, Marsh W, Doyle LA, Ellison G, Grever M, Ringel MD, Villalona-Calero MA. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol. 2011;29:2357-2363. [PMID: 21519026 DOI: 10.1200/jco2010.33.9473] [Reference Citation Analysis]
114 Ma KW, Cheung TT, Leung B, She BWH, Chok KSH, Chan ACY, Dai WC, Lo CM. Adjuvant chemotherapy improves oncological outcomes of resectable intrahepatic cholangiocarcinoma: A meta-analysis. Medicine (Baltimore). 2019;98:e14013. [PMID: 30702559 DOI: 10.1097/md.0000000000014013] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
115 Lee YG, Han SW, Oh DY, Chie EK, Jang JY, Im SA, Kim TY, Kim SW, Ha SW, Bang YJ. Diagnostic performance of contrast enhanced CT and 18F-FDG PET/CT in suspicious recurrence of biliary tract cancer after curative resection. BMC Cancer 2011;11:188. [PMID: 21599995 DOI: 10.1186/1471-2407-11-188] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
116 Sasaki T, Isayama H, Nakai Y, Mizuno S, Yamamoto K, Yagioka H, Yashima Y, Kawakubo K, Kogure H, Togawa O. Feasibility study of gemcitabine and cisplatin combination chemotherapy for patients with refractory biliary tract cancer. Invest New Drugs. 2011;29:1488-1493. [PMID: 20607585 DOI: 10.1007/s10637-010-9485-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
117 Sasaki T, Isayama H, Nakai Y, Takahara N, Sasahira N, Kogure H, Mizuno S, Yagioka H, Ito Y, Yamamoto N. Improvement of prognosis for unresectable biliary tract cancer. World J Gastroenterol. 2013;19:72-77. [PMID: 23326165 DOI: 10.3748/wjg.v19.i1.72] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
118 Wada Y, Shimada M, Yamamura K, Toshima T, Banwait JK, Morine Y, Ikemoto T, Saito Y, Baba H, Mori M, Goel A. A Transcriptomic Signature for Risk-Stratification and Recurrence Prediction in Intrahepatic Cholangiocarcinoma. Hepatology 2021. [PMID: 33725402 DOI: 10.1002/hep.31803] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
119 Sicklick JK, Fanta PT, Shimabukuro K, Kurzrock R. Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design. Cancer Metastasis Rev. 2016;35:263-275. [PMID: 26857926 DOI: 10.1007/s10555-016-9602-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
120 Kaufman M, Mehrotra B, Limaye S, White S, Fuchs A, Lebowicz Y, Nissel-Horowitz S, Thomas A. EGFR expression in gallbladder carcinoma in North America. Int J Med Sci 2008;5:285-91. [PMID: 18825277 DOI: 10.7150/ijms.5.285] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
121 Oh SY, Jeong CY, Hong SC, Kim TH, Ha CY, Kim HJ, Lee G, Hwang IG, Jang JS, Kwon H, Kang JH. Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness. Invest New Drugs 2011;29:1066-72. [DOI: 10.1007/s10637-010-9417-3] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 3.5] [Reference Citation Analysis]
122 Poultsides GA, Zhu AX, Choti MA, Pawlik TM. Intrahepatic cholangiocarcinoma. Surg Clin North Am. 2010;90:817-837. [PMID: 20637950 DOI: 10.1016/j.suc.2010.04.011] [Cited by in Crossref: 78] [Cited by in F6Publishing: 64] [Article Influence: 7.1] [Reference Citation Analysis]
123 Shah UA, Nandikolla AG, Rajdev L. Immunotherapeutic Approaches to Biliary Cancer. Curr Treat Options Oncol 2017;18:44. [PMID: 28660602 DOI: 10.1007/s11864-017-0486-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
124 Wang Y, Ding M, Zhang Q, Wang J, Yang X, Zhou F, Li L, Yuan Z, Jin H, Qian Q. Activation or suppression of the immune response mediators in biliary tract cancer (BTC) patients: a systematic review and meta-analysis. J Cancer 2017;8:74-84. [PMID: 28123600 DOI: 10.7150/jca.16774] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
125 Elmoghazy W, Cowan J, Tabchouri N, Tinguely P, Bennamoun M, Tubbax C, Sarran A, Lefevre M, Lamer C, Gayet B, Fuks D. Liver resection for extra-pancreatic biliary cancer: what is the role of laparoscopic approach? Surg Endosc 2019;33:3711-7. [PMID: 30693390 DOI: 10.1007/s00464-019-06664-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
126 Lu Q, Fang T. Circular RNA SMARCA5 correlates with favorable clinical tumor features and prognosis, and increases chemotherapy sensitivity in intrahepatic cholangiocarcinoma. J Clin Lab Anal 2020;34:e23138. [PMID: 31880360 DOI: 10.1002/jcla.23138] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
127 Hwang IG, Jang JS, Do JH, Kang JH, Lee GW, Oh SY, Kwon HC, Jun HJ, Lim HY, Lee S, Chi KC, Lee SJ. Different relation between ERCC1 overexpression and treatment outcomes of two platinum agents in advanced biliary tract adenocarcinoma patients. Cancer Chemother Pharmacol 2011;68:935-44. [DOI: 10.1007/s00280-011-1558-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
128 Sahani DV, Hayano K, Galluzzo A, Zhu AX. Measuring Treatment Response to Systemic Therapy and Predicting Outcome in Biliary Tract Cancer: Comparing Tumor Size, Volume, Density, and Metabolism. American Journal of Roentgenology 2015;204:776-81. [DOI: 10.2214/ajr.14.13223] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
129 Capdevila J, Ramos FJ, Macarulla T, Elez E, Ruiz-echarri M, Perez-garcia J, Tabernero J. Development of new drug strategies in infrequent digestive tumors: esophageal, biliary tract, and anal cancers. Current Opinion in Oncology 2009;21:374-80. [DOI: 10.1097/cco.0b013e32832c9464] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
130 Mao Z, Zhu G, Ren L, Guo X, Su D, Bai L. Prognostic Value of C-met Expression in Cholangiocarcinoma. Technol Cancer Res Treat 2016;15:227-33. [DOI: 10.1177/1533034615578959] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
131 Lowery MA, Goff LW, Keenan BP, Jordan E, Wang R, Bocobo AG, Chou JF, O'Reilly EM, Harding JJ, Kemeny N, Capanu M, Griffin AC, McGuire J, Venook AP, Abou-Alfa GK, Kelley RK. Second-line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes. Cancer. 2019;125:4426-4434. [PMID: 31454426 DOI: 10.1002/cncr.32463] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
132 Takashima A, Morizane C, Ishii H, Nakamura K, Fukuda H, Okusaka T, Furuse J. Randomized phase II study of gemcitabine plus S-1 combination therapy vs. S-1 in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG0805). Jpn J Clin Oncol 2010;40:1189-91. [PMID: 20630899 DOI: 10.1093/jjco/hyq110] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
133 Kim KP, Jang G, Hong YS, Lim HS, Bae KS, Kim HS, Lee SS, Shin JG, Lee JL, Ryu MH, Chang HM, Kang YK, Kim TW. Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity. Br J Cancer 2011;104:605-12. [PMID: 21326246 DOI: 10.1038/bjc.2011.17] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
134 Lim K, Han S, Oh D, Im S, Kim T, Bang Y. Outcome of Infusional 5-Fluorouracil, Doxorubicin, and Mitomycin-C (iFAM) Chemotherapy and Analysis of Prognostic Factors in Patients with Refractory Advanced Biliary Tract Cancer. Oncology 2012;83:57-66. [DOI: 10.1159/000338795] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
135 Kang MJ, Lee JL, Kim TW, Lee SS, Ahn S, Park do H, Lee SS, Seo DW, Lee SK, Kim MH. Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma. Acta Oncol. 2012;51:860-866. [PMID: 22559158 DOI: 10.3109/0284186x.2012.682628] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
136 Jones O, Cheng X, Murthy SRK, Ly L, Zhuang T, Basadonna G, Keidar M, Canady J. The synergistic effect of Canady Helios cold atmospheric plasma and a FOLFIRINOX regimen for the treatment of cholangiocarcinoma in vitro. Sci Rep 2021;11:8967. [PMID: 33903679 DOI: 10.1038/s41598-021-88451-w] [Reference Citation Analysis]
137 Maurya SK, Tewari M, Mishra RR, Shukla HS. Genetic abberations in gallbladder cancer. Surgical Oncology 2012;21:37-43. [DOI: 10.1016/j.suronc.2010.09.003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]